When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Direct factor Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

   Side effects may include bleeding, most commonly from the nose, gastrointestinal tract (GI) or genitourinary system. [2] Compared to the risk of bleeding with warfarin use, direct factor Xa inhibitors have a higher risk of GI bleeding, but lower risk of bleeding in the brain. [2]

3. Rivaroxaban - Wikipedia

   en.wikipedia.org/wiki/Rivaroxaban

   Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. [8] Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. [ 8 ]

4. Discovery and development of direct Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Discovery_and_development...

   Rivaroxaban (Xarelto) was the first approved FXa inhibitor to become commercially available in Europe and Canada in 2008. [1] The second one was apixaban (Eliquis), approved in Europe in 2011 [2] and in the United States in 2012. [3] The third one edoxaban (Lixiana, Savaysa) was approved in Japan in 2011 and in Europe and the US in 2015. [4]

5. J&J, Bristol Myers lose challenges to US drug price ...

   www.aol.com/news/j-j-bristol-myers-lose...

   Eliquis brought Bristol Myers about $8.52 billion in U.S. sales last year, while J&J recorded $2.36 billion in Xarelto sales. Eliquis is shared with Pfizer and Xarelto with Bayer, which were not ...

6. Xarelto Makers Created 'False Narrative' in Phila. Trial ...

   www.aol.com/news/xarelto-makers-created-apos...

   For premium support please call: 800-290-4726 more ways to reach us

7. FDA approves new pain medication as an alternative to opioids ...

   www.aol.com/fda-approves-pain-medication...

   For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...